a n a ly s i s Genome-wide association studies (GWAS) have proven to be a powerful method to identify common genetic variants contributing to susceptibility to common diseases. Here, we show that extremely low-coverage sequencing (0.1-0.5×) captures almost as much of the common (>5%) and low-frequency (1-5%) variation across the genome as SNP arrays. As an empirical demonstration, we show that genome-wide SNP genotypes can be inferred at a mean r 2 of 0.71 using off-target data (0.24× average coverage) in a whole-exome study of 909 samples. Using both simulated and real exome-sequencing data sets, we show that association statistics obtained using extremely low-coverage sequencing data attain similar P values at known associated variants as data from genotyping arrays, without an excess of false positives. Within the context of reductions in sample preparation and sequencing costs, funds invested in extremely low-coverage sequencing can yield several times the effective sample size of GWAS based on SNP array data and a commensurate increase in statistical power.
a n a ly s i s we used the squared correlation (r 2 ) between imputed dosages and true genotypes, which quantifies the reduction in effective sample size in GWAS due to imperfect imputation 13 (Online Methods).
The accuracy of imputation, either using just the sequencing reads to impute genotypes or using the reads coupled with the 1000 Genomes Project reference panels 2 (Online Methods), are shown ( Fig. 1) . We observed high accuracies at extremely low coverage (0.1-0.5×) when reference panels were used ( Fig. 1, Supplementary  Fig. 1 and Supplementary Note). Sequencing at 0.2× coverage yielded more than 90% of the effective sample size that was achieved by Illumina Human-1M-Duo array plus conventional imputation, as assessed by average r 2 to SNPs in the 1000 Genomes Project data set for both common (>5% minor allele frequency) as well as lowfrequency (1-5% minor allele frequency) variants (Fig. 1) . These simulation results suggest that sequencing at 0.1-0.5× coverage with imputation using the 1000 Genomes Project data sets can, in principle, achieve power comparable to high-density SNP arrays. These simulation results are robust to model assumptions and parameter values (Supplementary Tables 1-3 and Supplementary Note).
We investigated whether similar results could be achieved with real data by analyzing whole-exome sequencing data from 909 individuals of European ancestry, combining samples from the International HIV Controllers Study (IHCS) (84), Swedish Schizophrenia Study (SCZ) (503) and Autism National Institute of Mental Health (NIMH) Controls Study (AUT) (322) (Online Methods) [14] [15] [16] [17] [18] . Whole-exome studies enrich the sample DNA for genic content before sequencing 3, 19, 20 and usually discard data from non-exonic regions. However, current DNA capture technologies do not yield perfect enrichment, and off-target data can often be substantial, given the high coverage of many exome-sequencing studies. For example, in the 909 exomes included, the average coverage was 0.24× for non-exonic regions and more than 60× for exons ( Supplementary Fig. 2 and Supplementary Note). We explored whether the whole-exome data, coupled with imputation based on the 1000 Genomes Project reference data set, could support a GWAS. We imputed genotypes at all polymorphic sites indentified in the European samples of the 1000 Genomes Project, using sequencing data together with the 762 haplotypes inferred from the European samples of the 1000 Genomes Project Phase 1 data (Online Methods), and quantified accuracy by comparing imputed calls with Illumina array genotyping calls (Online Methods). To remove effects of high coverage at or near exons, we removed data at all SNPs covered at more than 4× (Supplementary Fig. 2 ). At 0.24× coverage, we observed an average r 2 = 0.71 (s.d. = 0.15) to the genotype calls assayed by genomewide SNP arrays, roughly similar in average expected power to a conventional GWAS with 71% of the sample size ( Supplementary  Fig. 3, Supplementary Table 4 , results averaged by chromosome, minor allele frequency and coverage, and Supplementary Note). We also quantified the genome-wide accuracy achieved by using all data from the whole-exome scan (off-target and on-target data); the average r 2 value increased to 0.77 when all data from the wholeexome study were used.
To illustrate how this approach might be used in practice to carry out a GWAS, we used the off-target exome data to compute association statistics at 103,977 SNPs across the genome using simulated phenotypes starting from the genotype calls from the arrays (Online Methods). We observed similar association statistics when imputed dosages were used compared to SNP arrays under both null (phenotype uncorrelated to the genotype) and true nonzero effect sizes (Fig. 2, Supplementary Figs. 4-6 and Supplementary Table 5), indicating that our approach is robust to false positives, while accurately recovering the association signal when present. In addition, we also performed a case-control scan in which the AUT samples were treated as controls and the SCZ samples were defined as cases. After adjusting for differences in genetic ancestry between the SCZ and AUT samples, we observed no association at genome-wide significance, thus further emphasizing the robustness of our approach ( Supplementary Fig. 7 and Supplementary Note). To assess the power of detecting true positives, in addition to simulated phenotypes, we also carried out a case-control study comparing HIV-1 controllers (61) and progressors (23) from the IHCS data set (Online Methods). The higher off-target coverage (0.5×) in the IHCS data led to an average of r 2 = 0.82 to the genotype calls at the 398,098 SNPs assayed by arrays in the IHCS data 14 . A similar λ GC (genomic control) 21 value of 1.05 for imputed npg a n a ly s i s data compared to 1.04 for directly genotyped data was observed ( Supplementary Fig. 4 and Supplementary Note). We specifically analyzed SNPs that were previously reported to be significantly associated with HIV-1 controller status 14 and observed similar association statistics and effect sizes compared to SNP arrays, both for the entire set of 47 previously associated SNPs (Supplementary Table 5 and Supplementary Note) and for the subset of 10 SNPs with nominal P < 0.05 in the SNP array data ( Table 1 ). The association statistics obtained using extremely low-coverage sequencing did not show the 9% drop that might have been expected given the r 2 = 0.91 imputation accuracy at these SNPs (ratio between the average −log 10 P values at imputed versus genotyped data of 1.04), but this can be explained by statistical fluctuation ( Table 1 and Supplementary Note).
We also evaluated empirical results at lower coverage (0.005-0.5×) by subsampling reads with corresponding probability. Because of the large number of experiments and the higher non-exome coverage of the IHCS data compared to all the 909 samples, we restricted this analysis to the 10 distinct 5-Mb regions (total of 50 Mb) in the IHCS data set (84 samples). As coverage decreased, we observed a reduction in accuracy, analogous to our simulations based on the 1000 Genomes Project data set, restricted to the same set of 6,070 SNPs from the array (Fig. 3) . At 0.5× coverage, we observed a mean r 2 of 0.82, with s.d. of 0.03 and standard error of 0.01 across the ten regions. However, the accuracy of imputation in the IHCS sequencing data was lower than in simulations for any level of coverage (Fig. 3) . The discrepancy between simulations and real data could be an effect of increased similarity across haplotypes inferred from the 1000 Genomes Project Phase 1 data due to the genotype calling and phasing procedure from 4× sequencing data that aggregated information across samples (Supplementary Table 6 and Supplementary Note). Other possible explanations include nonuniform error rates in base-calling and alignment of reads across the genome or simulation parameters that do not perfectly model aspects of the empirical data, such as variance in coverage across samples and loci, although our experiments suggest that these are unlikely to be the primary explanations (Supplementary Note).
DISCUSSION
To explore the economic ramifications of sequencing-based GWAS, we considered the tradeoff between the number of samples sequenced and average coverage (which affects accuracy). We evaluated the expected effective sample size attained with different strategies and compared this with the effective sample size that would be obtained by genotyping using standard genotyping arrays (for example, the Illumina Human-1M-Duo array). We derived all results from empirical accuracies using sequencing data sets subsampled from the IHCS data, so that results did not rely on any simulation assumptions. We compared accuracies only at SNPs genotyped on the array, a conservative computation that ignored the potentially greater benefit at SNPs not present on the array. We assumed a fixed total budget of $300,000, an arbitrarily large number of samples available, a sample preparation cost of $30 (conservatively double the cost that we have recently shown 11 ) and DNA sequencing cost of $133 per 1× sequencing (based on the Illumina Network cost of $4,000 for 30× sequencing of 50 samples or more, which scales linearly with lower coverage). We calculated the effective sample size of a sequencing-based GWAS as a function of average coverage, which determines the number of samples sequenced under a fixed budget (Online Methods). Under zero sample preparation cost and ignoring the benefit of imputation, the optimal study design involves sequencing a maximal number of samples at minimal coverage 22, 23 . However, when sample preparation cost and imputation are taken into account, there is an optimal number of samples to sequence for any budget. For a fixed budget of $300,000, the highest effective sample size (roughly equivalent to more than 4,600 genotyped individuals) is achieved at an average coverage of 0.1× (6,800 samples sequenced at $45 total cost per npg a n a ly s i s sample, r 2 = 0.65) (Fig. 4a) . The optimal value of average coverage varies as a function of sample preparation and sequencing costs, but we obtained qualitatively similar results for other cost assumptions (Supplementary Note). We note that a sequencing-based approach can attain a higher effective sample size than SNP arrays, even when constraints on sample availability limit the space of available study designs (Fig. 4a) . A notable finding is that the effective sample size achieved using sequencing-based GWAS with current costs 11 is more than six times higher than SNP-array genotyping at $400 per sample, corresponding to a large increase in power (Fig. 4b, Supplementary Fig. 8 and Supplementary Note). Only if SNP array genotyping is less than $70 per sample or if sample preparation and sequencing costs are much higher (for example, greater than $120 per sample for sample preparation or $1,000 for 1× sequencing) does sequencing-based GWAS lose its advantage in terms of statistical power to associate variants. If sequencing technology-both in terms of the efficiency of library preparation and the cost of sequencing-continues to improve more quickly than genotyping technology, the advantage of sequencing-based GWAS will increase. We note that a critical ingredient for attaining high accuracy at extremely low coverage is the availability of large panels of reference haplotypes. As additional reference haplotypes over larger numbers of SNPs become available from the 1000 Genomes Project and other projects, we expect the accuracy attained by extremely low-coverage sequencing to further increase.
We conclude with several caveats. First, computational methods for sequencing-based GWAS are still under development 3, 7, 22, 24 , whereas the SNP array-based GWAS is a proven method that produces high-quality data that can be analyzed using readily available computational tools. Second, sequencing data require additional computational resources beyond what is necessary to analyze conventional GWAS data, as the analysis pipeline for sequencing data is typically more demanding than for genotyping data. Third, sequencing-based GWAS of the type described here do not involve sufficient coverage to discover rare variants and to associate them with disease; thus, as with SNP arrays, the power of this approach is limited to common and (to a lesser extent) low-frequency variants. Fourth, although results from our empirical IHCS sequencing data are encouraging, no study to date has used sequencing-based GWAS to identify new disease risk variants. A priority for future work should be to carry out studies that show that this approach can be used to discover new associations between genetic variants and common diseases. 
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Accession codes. AUT data (phs000298.v1) and SCZ data (phs000473. v1.p1) have been deposited at dbGaP. IHCS data are available by direct request from P. Richtmyer (prichtmyer@partners.org); investigators can submit a concept sheet detailing their study design, research questions and other needs in order to request access to IHCS genetic data. The concept sheet with detailed instructions can be downloaded (see URLs). Requests will be reviewed on the basis npg a n a ly s i s of scientific merit, feasibility and potential overlap with accepted concept sheets or ongoing investigations.
